Non-antibacterial tetracyclines demonstrate disease protection in preclinical studies
Paratek Pharmaceuticals, Inc. announced results of preclinical studies demonstrating that a new class of compounds, orally available non-antibacterial tetracyclines, has shown promising activity in a preclinical animal model of multiple sclerosis (MS). Affecting approximately two million people worldwide, MS is a chronic, inflammatory condition of the nervous system and the most common, non-traumatic, neurological disease in young adults. Dr. David McKenney, a Paratek scientist, will present the findings during an oral presentation at 2:30 p.m. PST (5:30 p.m. EST) today at Neuroscience 2004, the Society for Neuroscience's 34th Annual Meeting in San Diego.
For the first time, Paratek is presenting data showing that its non-antibacterial tetracycline compounds in a preclinical model of MS have efficacy comparable to minocycline, an antibiotic also in the tetracycline family. A previous clinical study directed by Dr. Luanne Metz at the University of Calgary has demonstrated disease protection in MS patients treated with minocycline. Unfortunately, long-term treatment with minocycline or any other broad-spectrum antibiotics causes many patients to experience intolerability related to antibiotic side effects. In today's presentation, Paratek will report that three non-antibacterial tetracycline compounds, with different structures, demonstrated activity in reducing limb paralysis in the preclinical EAE (Experimental Autoimmune Encephalomyelitis) model of MS. These compounds have no detectable antibacterial activity.
Paratek Pharmaceuticals, Inc. and Serono (virt-x: SEO and NYSE: SRA) announced today that they have entered into an agreement to discover, develop and commercialize an orally-available disease modifying treatment for multiple sclerosis (MS). The agreement covers the compounds for which Dr. McKenney presents data today.
Stuart Levy, Paratek's Vice Chairman, Chief Scientific Officer and Co-Founder, commented, "The clinical research community has long regarded a pill for MS as an ultimate goal, but so far attempts to develop a safe, feasible, orally available drug candidate have failed. Our team has successfully modified the tetracycline molecule, keeping the core structure that confers anti-MS activity while removing portions of the molecule with antibacterial effects. This represents an exciting advance not only for MS, but potentially for many other inflammation-related disease areas. "
Dr. Michael Draper, Associate Director at Paratek, stated, "Paratek has developed world-class expertise in modifying the tetracycline class, which has a 30-year track record in the marketplace and a favorable, well-documented safety profile. This new, proprietary class of non-antibacterial tetracycline compounds will avoid the negative consequences associated with long-term antibiotic use and will not further contribute to the development of antibiotic resistance. We believe that these highly active, orally available compounds will also prove to be well-tolerated for MS, and we are very proud of this accomplishment."
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
It is never too late to be what you might have been.
-- George Eliot